Payment overview · 2025
General Payments
$524.43
13 reported records · 11 companies
Healthcare provider profile · identity verified
Patrick Shawn Drummond, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · MEMPHIS, TN · NPI 1295936821
Verified facts
What the public records show
CMS Open Payments records show Patrick Shawn Drummond, APRN received $524.43 in general payments during 2025 across 13 reported records.
Abbott Laboratories accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $118.51 | 22.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $117.21 | 22.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $82.26 | 15.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.18 | 10.9% | 2 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $34.74 | 6.6% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $30.93 | 5.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.06 | 4.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $22.46 | 4.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.28 | 2.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.72 | 2.8% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $8.08 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $524.43 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $118.51 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $117.21 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $82.26 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.18 | 2 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $34.74 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $30.93 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $25.71 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $8.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 23 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
89 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 525 | 183 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 101 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 288 | 108 |
| Metformin Hcl Er | Metformin Hcl | 280 | 90 |
| Carvedilol | Carvedilol | 244 | 89 |
| Losartan Potassium | Losartan Potassium | 178 | 71 |
| Lisinopril | Lisinopril | 177 | 64 |
| Meloxicam | Meloxicam | 163 | 57 |
| Gabapentin | Gabapentin | 162 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 48 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 146 | 48 |
| Omeprazole | Omeprazole | 138 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 36 |
| Furosemide | Furosemide | 114 | 39 |
| Potassium Chloride | Potassium Chloride | 113 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 108 | 40 |
| Trazodone Hcl | Trazodone Hcl | 96 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 93 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 48 |
| Ozempic | Semaglutide | 91 | 26 |
| Farxiga | Dapagliflozin Propanediol | 89 | 35 |
| Donepezil Hcl | Donepezil Hcl | 80 | 17 |
| Allopurinol | Allopurinol | 72 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 32 |
| Eliquis | Apixaban | 64 | 17 |
| Simvastatin | Simvastatin | 64 | 16 |
| Prednisone | Prednisone | 62 | 49 |
| Benazepril Hcl | Benazepril Hcl | 61 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 54 | 18 |
| Ibuprofen | Ibuprofen | 52 | 28 |
| Spironolactone | Spironolactone | 52 | 12 |
| Jardiance | Empagliflozin | 49 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 49 | 19 |
| Famotidine | Famotidine | 48 | 18 |
| Pregabalin | Pregabalin | 48 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 22 |
| Glimepiride | Glimepiride | 46 | 16 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Methimazole | Methimazole | 44 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 44 | 20 |
| Chlorthalidone | Chlorthalidone | 42 | 16 |
| Baclofen | Baclofen | 40 | 19 |
| Mirtazapine | Mirtazapine | 40 | 19 |
| Montelukast Sodium | Montelukast Sodium | 38 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 12 |
| Tradjenta | Linagliptin | 36 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 34 | suppressed |
| Ezetimibe | Ezetimibe | 31 | 17 |
| Lovastatin | Lovastatin | 31 | 11 |
| Metformin Hcl | Metformin Hcl | 31 | suppressed |
| Finasteride | Finasteride | 30 | 11 |
| Naproxen | Naproxen | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 26 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | 14 |
| Cilostazol | Cilostazol | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Atenolol | Atenolol | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 14 |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Austedo | Deutetrabenazine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $524.43 · 13 records | Abbott Laboratories | AIRSUPRA, AREXVY, COLLAGENASE SANTYL, Cologuard Collection Kit, FREESTYLE LIBRE 3, INGREZZA, Kerendia, Miro3D, Ozempic, REPATHA, TRELEGY ELLIPTA, Topical Oxygen Chamber for extremities | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error